Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CareDx, Inc.CDNA · Entity 4344 | Director | August 05, 2026 | August 06, 2026 |
| INOVIO PHARMACEUTICALS, INC.INO · Entity 6589 | Director | March 21, 2018 | March 22, 2018 |
| Innoviva, Inc.INVA · Entity 4679 | Director | April 25, 2022 | April 27, 2022 |
| Sio Gene Therapies Inc.AXGT · Entity 130622 | Director | April 15, 2019 | April 18, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CareDx, Inc.
Report date August 05, 2026 · Filed August 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 134,061 |
Reported balance
After 2026-08-05 transaction · row 1
1 source rowRow 1 · 2026-08-05 · Sale · Disposed 20,000 · Balance 134,061 F1: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.14 to $47.06 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.14 to $47.06 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
INOVIO PHARMACEUTICALS, INC.
Report date March 21, 2018 · Filed March 22, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,090 |
Reported balance
After 2018-03-21 transaction · row 1
1 source rowRow 1 · 2018-03-21 · Exercise / conversion · Acquired 4,090 · Balance 4,090 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,270 restricted stock units is as follows: 4,090 shares vested on March 21, 2018; 4,090 shares will vest on March 21, 2019; 4,090 shares will vest on March 21, 2020. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 8,180 |
Reported balance
After 2018-03-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-03-21 · Exercise / conversion · Disposed 4,090 · Balance 8,180 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,270 restricted stock units is as follows: 4,090 shares vested on March 21, 2018; 4,090 shares will vest on March 21, 2019; 4,090 shares will vest on March 21, 2020. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,270 restricted stock units is as follows: 4,090 shares vested on March 21, 2018; 4,090 shares will vest on March 21, 2019; 4,090 shares will vest on March 21, 2020. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both.
Innoviva, Inc.
Report date April 25, 2022 · Filed April 27, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 137,207 |
Reported balance
After 2022-04-25 transaction · row 1
1 source rowRow 1 · 2022-04-25 · Grant · Acquired 12,647 · Balance 137,207 F1: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2022 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. |
| Non-statutory Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $17.79 · Expires 2032-04-24 | Direct | 10,000 |
Reported balance
After 2022-04-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-04-25 · Grant · Acquired 10,000 · Balance 10,000 F1: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2022 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2022 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date.
Sio Gene Therapies Inc.
Report date April 15, 2019 · Filed April 18, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.06 · Expires 2029-04-14 | Direct | 255,000 |
Reported balance
After 2019-04-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-04-15 · Grant · Acquired 255,000 · Balance 255,000 F1: 100% of this option will vest on April 15, 2020, subject to the Reporting Person providing continuous service to the Issuer on such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of this option will vest on April 15, 2020, subject to the Reporting Person providing continuous service to the Issuer on such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ARIAD PHARMACEUTICALS INC
Report date February 16, 2017 · Filed February 16, 2017
Section 16 reporting ended · disclosed 2017-02-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-02-16 transaction · row 1
1 source rowRow 1 · 2017-02-16 · Disposition to issuer · Disposed 18,008 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of January 8, 2017 (the "Merger Agreement"), between the Company, Takeda Pharmaceutical Company Limited ("Takeda") and Kiku Merger Co., Inc. ("Purchaser"), on February 16, 2017, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $24.00 in cash. F2: The number of Shares reported includes 5,508 unvested restricted Shares subject to a lapsing right of repurchase by the Company (each, a "Restricted Share") and 12,500 Shares underlying unvested restricted stock units (each, an "RSU"). By virtue of the Merger and without any required action on the part of the holder thereof, all vesting conditions and restrictions applicable to each Restricted Share lapsed and each Restricted Share was converted automatically into the right to receive $24.00 in cash. In addition, pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Merger automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Merger into a vested right to receive a lump-sum cash payment in an amount equal to $24.00 for each Share underlying the RSU, less any required withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.65 | Direct | 0 |
Reported balance
After 2017-02-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-02-16 · Disposition to issuer · Disposed 75,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.82 | Direct | 0 |
Reported balance
After 2017-02-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-02-16 · Disposition to issuer · Disposed 25,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of January 8, 2017 (the "Merger Agreement"), between the Company, Takeda Pharmaceutical Company Limited ("Takeda") and Kiku Merger Co., Inc. ("Purchaser"), on February 16, 2017, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $24.00 in cash.
F2: The number of Shares reported includes 5,508 unvested restricted Shares subject to a lapsing right of repurchase by the Company (each, a "Restricted Share") and 12,500 Shares underlying unvested restricted stock units (each, an "RSU"). By virtue of the Merger and without any required action on the part of the holder thereof, all vesting conditions and restrictions applicable to each Restricted Share lapsed and each Restricted Share was converted automatically into the right to receive $24.00 in cash. In addition, pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Merger automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Merger into a vested right to receive a lump-sum cash payment in an amount equal to $24.00 for each Share underlying the RSU, less any required withholding taxes.
F3: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 05, 2026 Filed Aug 6, 2026 20:10 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 20,000 | $46.29 | $925,700.00 |
DisclosureSEC source: 0001329646-26-000003 · form4-08062026_040803.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,061 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.14 to $47.06 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 21:48 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 9,795 | $0.00 | $0.00 |
DisclosureSEC source: 0001329646-26-000001 · form4-06162026_090635.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 154,061 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"), of which the RSUs vests 100% on the earlier of the one year anniversary of grant or the day immediately before the first Annual Meeting that occurs after the grant date., subject to the Reporting Person's continuous service on each applicable vesting date. Read SEC document |
| September 11, 2025 Filed Sep 12, 2025 21:09 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionStock Option (right to buy) · Derivative | 29,136 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001415889-25-024408 · form4-09122025_090941.xml · derivative · entry 2 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,136 shares Expires 2033-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on June 16, 2024. Read SEC document |
| September 11, 2025 Filed Sep 12, 2025 21:09 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 29,136 | $7.96 | $231,922.56 |
DisclosureSEC source: 0001415889-25-024408 · form4-09122025_090941.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,266 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 20:30 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 12,103 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-087413 · ownership.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,130 F1 · shares: The reported securities are represented by restricted stock units which shall vest in one installment on the earlier of (i) June 13, 2026 or (ii) the day immediately prior to the first annual meeting of stockholders held by CareDx, Inc. after June 13, 2025. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 20:30 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 20,000 | $18.36 | $367,102.00 |
DisclosureSEC source: 0000950170-25-037987 · ownership.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,027 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.0650 to $18.7100, inclusive. The Reporting Person undertakes to provide to CareDx, Inc., any security holder of CareDx, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4 Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:42 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionStock Option (right to buy) · Derivative | 2,226 | $0.00 Strike: $5.49 | $0.00 |
DisclosureSEC source: 0000950170-24-121567 · ownership.xml · derivative · entry 4 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,226 shares Expires 2024-11-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to this option vested fully on November 8, 2018. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:42 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionStock Option (right to buy) · Derivative | 5,255 | $0.00 Strike: $5.85 | $0.00 |
DisclosureSEC source: 0000950170-24-121567 · ownership.xml · derivative · entry 3 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,255 shares Expires 2025-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to this option vested fully on June 17, 2016. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:42 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 2,226 | $5.49 | $12,220.74 |
DisclosureSEC source: 0000950170-24-121567 · ownership.xml · nonDerivative · entry 2 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,027 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:42 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 5,255 | $5.85 | $30,741.75 |
DisclosureSEC source: 0000950170-24-121567 · ownership.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 20:41 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantStock Option (right to buy) · Derivative | 16,048 | $0.00 Strike: $9.35 | $0.00 |
DisclosureSEC source: 0000950170-24-074943 · ownership.xml · derivative · entry 2 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,048 Underlying: Common Stock · 16,048 shares Expires 2034-06-14 F2 · derivative.exercise_date: 1/12th of the shares subject to this option shall vest on July 14, 2024, and 1/12th of the shares subject to the option shall vest monthly thereafter through June 14, 2025. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 20:41 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 10,570 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-074943 · ownership.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,546 F1 · shares: The reported securities are represented by restricted stock units which shall vest in one installment on June 14, 2025. Read SEC document |
| June 14, 2024 Filed Jun 20, 2024 20:42 UTC Amendment | CareDx, Inc. CDNA · Entity 4344 | GrantStock Option (right to buy) · Derivative | 16,048 | $0.00 Strike: $14.19 | $0.00 |
DisclosureSEC source: 0000950170-24-075652 · ownership.xml · derivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,048 Underlying: Common Stock · 16,048 shares Expires 2034-06-14 F1 · derivative.exercise_price: This amendment is being filed to correct the exercise price of the derivative security of the Stock Option (right to buy) reported on the original Form 4. F2 · derivative.exercise_date: 1/12th of the shares subject to this option shall vest on July 14, 2024, and 1/12th of the shares subject to the option shall vest monthly thereafter through June 14, 2025. Read SEC document |
| May 14, 2024 Filed May 16, 2024 20:38 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionStock Option (right to buy) · Derivative | 5,255 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0000950170-24-061135 · ownership.xml · derivative · entry 2 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,255 shares Expires 2024-07-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/12 of the shares subject to the option vested on August 21, 2014, and 1/12 of the shares subject to the option vested monthly thereafter until fully vested. Read SEC document |
| May 14, 2024 Filed May 16, 2024 20:38 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 5,255 | $10.00 | $52,550.00 |
DisclosureSEC source: 0000950170-24-061135 · ownership.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,976 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 23:47 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionOption to Purchase Common Stock · Derivative | 4,453 | $0.00 Strike: $5.49 | $0.00 |
DisclosureSEC source: 0001217234-23-000186 · wf-form4_169179763523797.xml · derivative · entry 6 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,226 Underlying: Common Stock · 4,453 shares Expires 2024-11-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options vested in three equal installments based upon the Company's achievement of certain performance goals. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 23:47 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionStock Option (right to buy) · Derivative | 9,745 | $0.00 Strike: $4.95 | $0.00 |
DisclosureSEC source: 0001217234-23-000186 · wf-form4_169179763523797.xml · derivative · entry 5 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,745 shares Expires 2026-07-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/12th of the shares subject to the option vested on August 1, 2016 and the shares subject to the option vested monthly thereafter through July 1, 2017. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 23:47 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionStock Option (right to buy) · Derivative | 5,255 | $0.00 Strike: $5.02 | $0.00 |
DisclosureSEC source: 0001217234-23-000186 · wf-form4_169179763523797.xml · derivative · entry 4 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,255 shares Expires 2026-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/12th of the shares subject to the option vested on July 16, 2016 and 1/12th of the shares subject to the option vested monthly thereafter. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 23:47 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 4,453 | $5.49 | $24,446.97 |
DisclosureSEC source: 0001217234-23-000186 · wf-form4_169179763523797.xml · nonDerivative · entry 3 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 23:47 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 9,745 | $4.95 | $48,237.75 |
DisclosureSEC source: 0001217234-23-000186 · wf-form4_169179763523797.xml · nonDerivative · entry 2 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,268 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 23:47 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 5,255 | $5.02 | $26,380.10 |
DisclosureSEC source: 0001217234-23-000186 · wf-form4_169179763523797.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,523 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 22:49 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock · Derivative | 29,136 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001217234-23-000122 · wf-form4_168738778213486.xml · derivative · entry 2 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,136 Underlying: Common Stock · 29,136 shares Expires 2033-06-16 F2 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on July 16, 2023 and the shares subject to the option shall vest monthly thereafter through June 16, 2024. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 22:49 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 18,844 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-23-000122 · wf-form4_168738778213486.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,268 F1 · shares: The reported securities are represented by restricted stock units which shall vest on June 16, 2024. Read SEC document |
| January 06, 2023 Filed Jan 9, 2023 22:27 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 1,323 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-23-000010 · wf-form4_167330322707595.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,424 F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| November 23, 2022 Filed Nov 23, 2022 23:03 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001217234-22-000191 · wf-form4_166924460971670.xml · derivative · entry 2 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2027-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/12th of the shares subject to the option vested on August 13, 2017 and the remaining shares subject to the option vested monthly thereafter through July 13, 2018. Read SEC document |
| November 23, 2022 Filed Nov 23, 2022 23:03 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 15,000 | $1.22 | $18,300.00 |
DisclosureSEC source: 0001217234-22-000191 · wf-form4_166924460971670.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,101 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 04, 2022 Filed Oct 4, 2022 21:39 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 986 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-22-000172 · wf-form4_166491953623679.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,101 F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 20:33 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 812 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-22-000136 · wf-form4_165713960366590.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,115 F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 21:02 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock · Derivative | 7,606 | $0.00 Strike: $20.56 | $0.00 |
DisclosureSEC source: 0001217234-22-000117 · wf-form4_165584531810969.xml · derivative · entry 2 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,606 Underlying: Common Stock · 7,606 shares Expires 2032-06-16 F2 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on July 16, 2022 and the shares subject to the option shall vest monthly thereafter through June 16, 2023. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 21:02 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 4,863 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-22-000117 · wf-form4_165584531810969.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,303 F1 · shares: The reported securities are represented by restricted stock units which shall vest on June 16, 2023. Read SEC document |
| May 09, 2022 Filed May 10, 2022 22:20 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 223 | $22.46 | $5,008.58 |
DisclosureSEC source: 0001217234-22-000095 · wf-form4_165222122167829.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,440 F1 · shares: Represents a grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| April 25, 2022 Filed Apr 27, 2022 22:52 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantNon-statutory Stock Option · Derivative | 10,000 | $0.00 Strike: $17.79 | $0.00 |
DisclosureSEC source: 0001567619-22-009045 · doc1.xml · derivative · entry 2 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-04-24 F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2022 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| April 25, 2022 Filed Apr 27, 2022 22:52 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 12,647 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-009045 · doc1.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,207 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2022 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:48 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 481 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-22-000072 · wf-form4_164919165251725.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,217 F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 01:48 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 25,000 | $39.11 | $977,672.50 |
DisclosureSEC source: 0001217234-22-000058 · wf-form4_164618565965482.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,736 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.02 to $39.27, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares sold at each separate price. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 23:08 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 287 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-22-000013 · wf-form4_164151052361326.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,736 F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 20:39 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 196 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-21-000217 · wf-form4_163337993327929.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,449 F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 22:34 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 188 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-21-000164 · wf-form4_162561083660357.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,253 F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| June 16, 2021 Filed Jun 22, 2021 00:00 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantStock Option (right to buy) · Derivative | 1,812 | $0.00 Strike: $88.70 | $0.00 |
DisclosureSEC source: 0001217234-21-000144 · wf-form4_162432004099082.xml · derivative · entry 2 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,812 Underlying: Common Stock · 1,812 shares Expires 2031-06-16 F2 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on July 16, 2021 and the shares subject to the option shall vest monthly thereafter through June 16, 2022. Read SEC document |
| June 16, 2021 Filed Jun 22, 2021 00:00 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 1,127 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-21-000144 · wf-form4_162432004099082.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,065 F1 · shares: The reported securities are represented by restricted stock units which shall vest on June 16, 2022. Read SEC document |
| May 24, 2021 Filed May 25, 2021 22:44 UTC | Innoviva, Inc. INVA · Entity 4679 | PurchaseCommon Stock | 10,000 | $13.46 | $134,619.00 |
DisclosureSEC source: 0001567619-21-011167 · doc1.xml · nonDerivative · entry 2 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,560 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.24 to $13.54, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 21, 2021 Filed May 21, 2021 23:50 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 799 | $75.97 | $60,700.11 |
DisclosureSEC source: 0001217234-21-000107 · wf-form4_162164098901739.xml · nonDerivative · entry 2 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,938 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.90 to $76.02, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| May 21, 2021 Filed May 21, 2021 23:50 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 9,201 | $75.28 | $692,673.36 |
DisclosureSEC source: 0001217234-21-000107 · wf-form4_162164098901739.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,737 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.89 to $75.89, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| May 21, 2021 Filed May 25, 2021 22:44 UTC | Innoviva, Inc. INVA · Entity 4679 | PurchaseCommon Stock | 10,000 | $12.97 | $129,670.00 |
DisclosureSEC source: 0001567619-21-011167 · doc1.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,560 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.9650 to $12.9670, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 14, 2021 Filed May 21, 2021 00:16 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 17,482 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-010830 · doc1.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,560 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs") upon the conclusion of the Issuer's 2021 annual meeting of stockholders. 100% of the RSUs will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| May 12, 2021 Filed May 14, 2021 01:11 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 600 | $63.75 | $38,248.02 |
DisclosureSEC source: 0001217234-21-000103 · wf-form4_162095467069439.xml · nonDerivative · entry 2 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,938 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.74 to $63.76, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| May 12, 2021 Filed May 14, 2021 01:11 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 9,400 | $63.03 | $592,498.92 |
DisclosureSEC source: 0001217234-21-000103 · wf-form4_162095467069439.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,538 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.73 to $63.73, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 00:50 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 193 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-21-000065 · wf-form4_161767016332107.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,938 F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:08 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 258 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-21-000008 · wf-form4_160997452035725.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,745 F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| December 14, 2020 Filed Dec 15, 2020 00:50 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 2,076 | $72.84 | $151,218.95 |
DisclosureSEC source: 0001217234-20-000200 · wf-form4_160799340480498.xml · nonDerivative · entry 3 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,487 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $72.67 to $73.07, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.